1. Ливзан М.А., Костенко М.Б. Место пробиотической терапии в лечении и профилактике антибиотик-ассоциированной диареи. Лечащий врач. 2010; 10: 83–4.
2. Осипенко М.Ф., Бикбулатова Е.А., Холин С.И. Пробиотики в лечении диарейного синдрома. Фарматека. 2008; 13: 36–41.
3. Осипенко М.Ф., Бикбулатова Е.А. Антибиотико-ассоциированная диарея, подходы к диагностике и лечению. Фарматека. 2007; 13: 89.
4. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205–10.
5. Bouhnik Y, Raskine L, Simoneau G et al. The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am J Clin Nutrition 2004; 80 (6): 1658–64.
6. Bousvaros A, Guandalini S, Baldassano RN et al. A randomized, double-blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Diseases 2005; 11 (9): 833–9.
7. Buts JP. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci 2009; 54: 15–8.
8. Bibiloni R, Fedorak RN, Tannock GW et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100 (7): 1539–46.
9. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996; 64: 5225–32.
10. Chassaing B, Darfeuillemichaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterol 2011; 140 (6): 1720–8.
11. Comito D, Romano C. Dysbiosis in the pathogenesis of pediatric inflammatory bowel diseases. Int J Inflamm 2012; 2012: 687143.
12. Chiodini RJ, Van Kruiningen HJ, Thayer R. Possible role of mycobacteria in inflammatory bowel disease an unclassified Mycobacterium species isolated from patients with Crohn’s disease. Dig Dis Sci 1984; 29 (12): 1073–9.
13. Cui HH, Chen CL, Wang JD et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004; 10 (10): 1521–5.
14. Chen X, Kokkotou EG, Mustafa N et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both ivitro and in vivo and protects against Clostridium difficile toxin A-inducedenteritis. J Biol Chem 2006; 281: 24449–54.
15. De Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Advances in Biochemical Engineering. Biotechnology 2008; 111: 1–66.
16. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002.
17. Feillet H, Bach JF. Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden? Curr Opin Gastroenterol 2004; 20560–564.
18. Joossens M, Huys G, Cnockaert M et al. Dysbiosis of the faecalmicrobiota in patients with Crohn’s disease and their unaffected relatives. Gut 2011; 60 (5): 631–7.
19. Kruis W, Frič P, Pokrotnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53 (11): 1617–23.
20. Looijer-van Langen MAC, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis 2009; 15 (3): 454–62.
21. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Systematic Reviews 2007; 4: CD005573.
22. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812–22.
23. Mowat C, Cole A, Windsor A et al. IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60 (5): 571–607.
24. Nagalingam NA, Lynch SV. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2012; 18 (5): 968–80.
25. Oirard-Pipau F, Pompei A, Schneider S et al. Intestinal microflora, short chain and cellular fatty acids, influence ofa probiotic S. boulardii. Microb Ecology Health Dis 2002; 14: 220–7.
26. Oliva‐Hemker M, Fiocchi C. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis 2002; 8112–28.
27. Panes J, Bouhnik Y, Reinisch W, Stoker J et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 2013; 7 (7): 556–85; doi: 10.1016/j.crohns.2013.02.020. Epub 2013.
28. Pothoulakis C. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther 2009; 30 (8): 826–33.
29. Rahimi R, Nikfar S, Rahimi F et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease. Dig Dis Sci 2008; 53 (9): 2524–31.
30. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118 (2): 229–41.
31. Rodemann JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339–44.
32. Surawicz CM, McFarland LV, Greenberg RN et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31 (4): 1012–7.
33. Tyakht АV, Kostryukova ES, Maev IV et al. Human gut microbiota community structures in urban and rural populations in Russia. Nature Communications 2013; 4: 2469; doi: 10.1038/ncomms3469.
34. Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Reports 2012; 14 (4): 324–33.
35. Willing BP, Dicksved J, Halfvarson J et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterol 2010; 139 (6): 1844.e1–54.e1.

М.Ф.Осипенко, М.И.Скалинская, А.А.Размерица

ГБОУ ВПО Новосибирский государственный медицинский университет Минздрава России